Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35266562/
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to relentless advances in molecular pathogenesis, prognostication, and newer treatments. MCL consists of a spectrum of clinical subtypes....
Conclusion/Relevance: Complex pathogenesis and the management of patients with progression after treatment with BTK/Bcl2 inhibitors and CAR-T (triple-resistant MCL) remains a challenge. Next-generation clinical trials incorporating newer agents and concurrent translational and molecular investigations are ongoing. This article provides a...
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882938/
Bushra Tbakhi, Conceptualization, Visualization, Writing original draft, Writing review editing and Patrick M. Reagan, Conceptualization, Supervision, Writing review editing Mantle cell lymphoma (MCL) is a rare B-cell malignancy that remains...
Relevance: This article provides an overview for the available management strategies for relapsed MCL and examines the role of CAR T-cell in the current and future treatment of MCL
Cystoid macular edema secondary to ibrutinib
Source : https://www.sciencedirect.com/science/article/pii/S2451993622001827?via=ihub
To describe a unique case of cystoid macular edema associated with Ibrutinib treatment for Chronic Lymphocytic Leukemia (CLL). A 73-year-old male patient presented to the ophthalmology clinic complaining of decreased...
Conclusions and Importance: Several novel oncologic therapies have been associated with CME in recent years. This case demonstrates an association between Ibrutinib an oral, irreversible inhibitor of Bruton's Tyrosine Kinase (BTK), and the development of CME. CME was resistant to topical treatment but resolved after treatment cessation. Along...
Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukemia? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35244285/
Infections with SARS-CoV-2 have been unduly severe in patients with hematological malignancies, in particular in those with chronic lymphocytic leukemia (CLL). Based on a series of observations, we propose that...
Conclusion/Relevance: Treatment of CLL with Bruton's tyrosine kinase (BTK) inhibitors increased the number of pDCs, likely secondarily to the reduction of the tumor burden.
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: an expert panel opinion statement - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35247223/
The introduction of BTK inhibitors transformed the management of patients with mantle cell lymphoma (MCL). Ibrutinib, the first-in-class BTK inhibitor is now approved in more than 80 countries and there...
Conclusion/Relevance: This expert opinion statement represents the panel's collective analysis, evaluation, and recommendations and is made up of a series of questions and answers (in the form of a review of the pertinent literature) designed to replicate those posed by practicing clinicians in Italy but which are applicable to clinical settings...